Page 143 - 71_04

VOL. 71 (4), 905-947, 2005 NUEVAS APROXIMACIONES PARA EL TRATAMIENTO...

JENNINGS, D. L.; KALUS, J. S. y O’DELL, K. M. (2005): Aldosterone receptor antago-
nism in heart failure. Pharmacotherapy. 25: 1126-1133.

KEATING, G. M. y PLOSKER, G. L. (2004): Eplerenone: a review of its use in left
ventricular systolic dysfunction and heart failure after acute myocardial infarc-
tion. Drugs. 64: 2689-2707.

NÚÑEZ FERNÁNDEZ, L. y TAMARGO MENÉNDEZ, J. L. (2005): Propiedades farmacológi-
cas de la eplerenona. En: EDM: Evaluación del Medicamento. Eplerenona. Ed.
Scientific Communication Management, S. L. Madrid. 5-25.

PITT, B.; REMME, W.; ZANNAD, F.; NEATON, J.; MARTINEZ, F.; RONIKER, B.; BITTMAN, R.;
HURLEY, S.; KLEIMAN, J. y GATLIN, M. (2003): Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone,
a selective aldosterone blocker, in patients with left ventricular dysfunction
after myocardial infarction. N. Engl. J. Med. 348: 1309-1321.

ROCHA, R.; RUDOLPH, A. E.; FRIERDICH, G. E.; NACHOWIAK, D. A.; KEKEC, B. K.; BLOMME,
E. A. et al. (2002): Aldosterone induces a vascular inflammatory phenotype in
the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283: H1802-H1810.

RUDOLPH, A. E.; ROCHA, R. y MCMAHON, E. G. (2004): Aldosterone target organ pro-
tection by eplerenone. Mol. Cell. Endocrinol. 217: 229-238.

ROSSI, G.; BOSCARO, M.; RONCONI, V. y FUNDER, J. W. (2005): Aldosterone as a cardio-
vascular risk factor. Trends Endocrinol. Metab. 16: 104-107.

STRUTHERS, A. D. y MACDONALD, T. M. (2004): Review of aldosterone- and angioten-
sin II-induced target organ damage and prevention. Cardiovasc. Res. 61: 663-
670.

TAMARGO, J.; CABALLERO, R.; GÓMEZ, R. y DELPÓN, E. (2003): Farmacología clínica de
las estatinas. Rev. Esp. Cardiol. 3 (Supl C): 2C-13C.

Insuficiencia cardiaca aguda y Levosimendan

FOLLATH, F.; CLELAND, J. G.; JUST, H.; PAPP, J. G.; SCHOLZ, H.; PEUHKURINEN, K.; HAR-
JOLA, V. P., et al.: Steering Committee and Investigators of the Levosimendan
Infusion versus Dobutamine (LIDO) Study (2002). Efficacy and safety of intra-
venous levosimendan compared with dobutamine in severe low-output heart
failure (the LIDO study): a randomised double-blind trial. Lancet. 360: 196-202.

GHEORGHIADE, M.; TEERLINK, J. R. y MEBAZAA, A. (2005): Pharmacology of new agents
for acute heart failure syndromes. Am. J. Cardiol. 96 (6A): 68G-73G.

INNES, C. A. y WAGSTAFF, A. J. (2003): Levosimendan: a review of its use in the
management of acute decompensated heart failure. Drugs. 63: 2651-2671.

LÓPEZ-SENDÓN, J. y TAMARGO, J. (2004): Bases y evidencias clínicas de los efectos de
los nuevos tratamientos farmacológicos en la insuficiencia cardíaca. Rev. Esp.
Cardiol. 57: 447-464.

MOISEYEV, V. S.; PODER, P.; ANDREJEVS, N., et al.: RUSSLAN Study Investigators
(2002): Safety and efficacy of a novel calcium sensitizer, levosimendan, in pa-
tients with left ventricular failure due to an acute myocardial infarction. A
randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J.
23: 1422-1432.

945